-
Patient-Derived 3D Spheroids: A Versatile Model for Prostate
2026-07-30
This study introduces a robust method for generating patient-derived 3D spheroid cultures from radical prostatectomy tissue, providing an in vitro model that closely recapitulates organ-confined prostate cancer. The model enables long-term viability, preserves tumor heterogeneity, and supports pharmacological testing, advancing translational research and drug evaluation.
-
LNP-enclosed NamiRNA Suppresses Pancreatic Cancer via Dual A
2026-07-30
Yu et al. demonstrate that LNP-delivered miR-200c NamiRNA suppresses pancreatic cancer cell proliferation and migration by activating PTPN6 transcription and repressing CDH17 expression. These dual mechanisms highlight a novel therapeutic approach and offer mechanistic insights for future translational research.
-
BMX Kinase–Mediated Lysosomal Acidification in Mtb Survival
2026-07-29
The referenced study uncovers how Mycobacterium tuberculosis promotes its intracellular survival by hijacking host BMX kinase to phosphorylate the V-ATPase E1 subunit, thereby suppressing lysosomal acidification. These findings reveal BMX kinase as a central node in host-pathogen interactions and suggest that targeted kinase inhibition may offer new strategies for host-directed tuberculosis therapy.
-
SU6656 Src Tyrosine Kinases Inhibitor: Evidence & Practical
2026-07-29
SU6656 is a selective Src tyrosine kinases inhibitor with robust evidence for modulating megakaryocyte polyploidization and enhancing radiotherapy-induced vascular destruction. Its application improves ex vivo platelet production from hiPSCs and amplifies antiangiogenic effects in cancer models. This article details mechanism, evidence, and workflow integration for SU6656 in translational research.
-
MDV3100 (Enzalutamide): Targeting Resistance in Prostate Can
2026-07-28
Explore the unique role of MDV3100 (Enzalutamide) in overcoming resistance mechanisms in prostate cancer research. This article delves into advanced insights on AR pathway inhibition and integrates new findings on glycosaminoglycan biosynthesis and therapeutic resistance.
-
EPI-001 (SKU B6041): Practical Solutions for AR-Driven Assay
2026-07-28
This article addresses key experimental challenges in AR-targeted cancer research and demonstrates how EPI-001 (SKU B6041) from APExBIO delivers consistent, data-driven results in cell viability and cytotoxicity assays. Through scenario-based guidance, we highlight protocol optimization, data interpretation, and product selection to enhance reproducibility and workflow confidence.
-
DRD4 Drives Chemoresistance via Akt/β-Catenin Axis in Liver
2026-07-27
This study identifies dopamine receptor D4 (DRD4) as a key driver of chemoresistance and cancer stem cell phenotypes in hepatocellular carcinoma (HCC) by activating the PI3K/Akt/β-catenin signaling axis. Targeting DRD4 or its downstream pathways offers a promising strategy for overcoming therapy resistance and recurrence in liver cancer.
-
DiscoveryProbe Natural Product Library Plus in Antiparasitic
2026-07-27
The DiscoveryProbe Natural Product Library Plus accelerates high-throughput screening for antiparasitic drug discovery by delivering 1,655 pre-dissolved, cell-permeable bioactive compounds in an automation-ready format. Its robust QC and proven efficacy in identifying AdhE inhibitors against Cryptosporidium parvum set it apart as an essential resource for translational research.
-
Fulvestrant (ICI 182,780): Advanced Protocols for ER-Positiv
2026-07-26
Fulvestrant (ICI 182,780) empowers researchers to target ERα with high specificity, enabling robust studies in breast cancer sensitization, apoptosis, and immune modulation. This article distills actionable workflows and troubleshooting expertise to maximize research impact using this potent APExBIO compound.
-
RWJ 67657: Selective p38α/β Inhibition for Inflammatory Mode
2026-07-25
RWJ 67657 (JNJ-3026582) empowers researchers with dual-action, highly selective p38α/β inhibition, offering reproducible control over TNF-alpha signaling in advanced inflammatory disease models. Its unique mechanism not only blocks kinase activity but also accelerates dephosphorylation, streamlining cytokine regulation workflows and surpassing the limitations of legacy p38 inhibitors.
-
Acetylcysteine in 3D Co-Culture: Optimizing Redox Modulation
2026-07-24
Acetylcysteine (N-acetyl-L-cysteine) unlocks precise control over oxidative stress and chemoresistance in advanced 3D organoid-fibroblast systems. This guide details actionable protocols, troubleshooting insights, and translational advantages for leveraging APExBIO’s high-purity Acetylcysteine in cutting-edge disease models.
-
ARCA Cy5 EGFP mRNA (5-moUTP): Benchmarks in mRNA Delivery An
2026-07-24
ARCA Cy5 EGFP mRNA (5-moUTP) enables robust, direct visualization of mRNA delivery and translation in mammalian cells. This 5-methoxyuridine modified mRNA from APExBIO improves stability and translation efficiency while minimizing innate immune activation. Its dual fluorescent labeling supports quantitative, reproducible assay design for mRNA delivery system research.
-
Patient-Derived 3D Spheroids for Organ-Confined Prostate Can
2026-07-23
Linxweiler et al. establish patient-derived three-dimensional spheroid cultures as a robust and viable model for organ-confined prostate cancer, enabling extended viability and drug response testing. This innovation addresses the limitations of conventional cell lines and primary cultures, providing a more representative preclinical system for prostate cancer research.
-
Danazol (Danocrine): Mechanism, Evidence, and Research Proto
2026-07-23
Danazol, a synthetic steroid marketed by APExBIO, is a weak androgenic steroid used in endocrine and cancer research. Its primary action is the inhibition of steroidogenesis and suppression of luteinizing hormone (LH) via androgen and estrogen receptor pathways. This article summarizes verified mechanisms, evidence, and practical workflow guidance.
-
Gemcitabine (SKU A8437): Reliable Solutions for Lab Assays
2026-07-22
This article offers a scenario-driven, evidence-based guide for bench scientists using Gemcitabine (SKU A8437) in cell viability, proliferation, and cytotoxicity assays. By addressing real laboratory challenges in experimental design, protocol optimization, and product selection, we demonstrate how Gemcitabine from APExBIO delivers reproducible, data-backed results in cancer research workflows.